You are a famous and esteemed scientist and professor in health economics with a proven track record of publications in top academic journals such as Journal of Health Economics, Health Economics, Social Science & Medicine, Annals of Internal Medicine, Lancet, JAMA, and BMJ. Your writing has a scientific rigor that ensures clarity and precision in language. I will give you points that cover the main content of each section (i.e., introduction, methods, results, and discussion), and you will use the points to write a paper that will be submitted to JAMA Network Open. Please use the writing style that fits the target journal. The language should be grammatically correct, and that the ideas are presented in a clear and concise manner. Please ensure the writing to meet the academic style, improve the spelling, grammar, clarity, concision and overall readability. Please use appropriate and precise words and sentences should flow fluently. Now, I will feed you the points of my abstract, and please use them to generate the abstract section. ABSTRACT
Background
Familial hypercholesterolemia is a prevalent genetic disorder with global implications for severe cardiovascular diseases. As the scrutiny on evaluating its economic impact intensifies, an imperative arises for a worldwide synthesis of economic evidence related to familial hypercholesterolemia screening. This study aims to globally examine economic assessments of familial hypercholesterolemia, synthesize evidence, and present economic insights into the impact of familial hypercholesterolemia screening on population equity.

Methods
A systematic literature review targeted economic evaluations of familial hypercholesterolemia screening. The quality appraisal of literature was guided by the quality of health economic studies instrument and consolidated health economic evaluation reporting standards 2022. Meta-analysis techniques were applied to integrate findings from various studies, focusing on the total cost-effectiveness and total net health benefit associated with both cascade and universal screening programs for familial hypercholesterolemia. An aggregate distributional cost-effectiveness analysis was employed to determine the potential impact of screening programs on health equity across populations.

Results
The study results reveal significant differences in the economic evaluations of familial hypercholesterolemia across different countries, and we provide detailed descriptions of unique characteristics. The combined results of cost-effectiveness analyses indicate that 90% of screening for familial hypercholesterolemia is cost-effective. Meta-analysis synthesized the economic impacts of seven sets of cascade and universal screening across diverse health outcomes. Aggregate distributional cost-effectiveness analysis showed that the difference was positive across all six studies, indicating that familial hypercholesterolemia screening strategy has the potential to mitigate health inequalities.

Conclusion
This study provides a global perspective on familial hypercholesterolemia economic evaluation. Despite international variations, findings suggest that, in the majority of cases, familial hypercholesterolemia screening is cost-effective, improving health equity and overall population health. The study offers a positive outlook for future health decisions.